Brief: EMA Fast Tracks Review Of Medicine For Metastatic Pancreatic Cancer
07/07/2026 13:35
BRIEF-EMA Fast Tracks Review Of Medicine For Metastatic Pancreatic Cancer July 7 (Reuters) - EMA:
EMA - BEGINS PHASED REVIEW OF DARAXONRASIB FOR METASTATIC PANCREATIC CANCER
EMA: FAST TRACKS REVIEW OF DARAXONRASIB FOR METASTATIC PANCREATIC CANCER
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Revolution Medicines
See all newsAnalysis: Revolution Medicines' Europe efforts signal solo launch ambitions for cancer drug
Brief: CHMP Recommends Granting Marketing Authorisation For Rasonque For Metastatic Pancreatic Cancer In EU
Revolution Medicines wins EU committee backing for pancreatic cancer treatment (updated)
EMA recommends approval of Revolution's pancreatic cancer drug
Revolution Medicines falls on pancreatic cancer drug data concerns